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A focus on the newer 
antibiotics targeting 
Gram-positive bacteria
The incidence of antimicrobial resistance has continued to rise with 
a threat to return to the “pre-antibiotic” era. This has included a 
sharp increase in multi-drug resistant organisms, which may cause 
life-threatening infections. Efforts have been made to develop new 
antibiotics with novel modes of action, aimed at acting against 
these multi-drug resistant strains. This review aims to focus on 
newly available and investigational antibiotics targeting Gram-
positive organisms. It is likely that these antibiotics will be used 
mainly in a secondary care setting; however primary care health 
care professionals also need to have an understanding of these 
antibiotics, since patients may be discharged home on them.
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Introduction
Antimicrobial resistance and the 
threat this brings with it have long 
been recognised. Inherent antimicrobial 
resistance existed even before 
antimicrobials were introduced into 
medicine; in 190, Abraham and Chain 
recognised acquired antimicrobial resistance 
when, during the development of penicillin, 
they isolated an enzyme (now termed 
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penicillinase) that destroys penicillin.1 
Due to the international and fast spread 
of microorganisms in this era of mass 
travel and global trade, the problem of 
antimicrobial resistance no longer remains 
a national one. Rather it is a European 
and global problem requiring international 
cooperation and a global strategy to avoid 
returning to the “pre-antibiotic” era. The 
inferior quality of poorly formulated or 
manufactured antimicrobials in the less 
developed world, where medications are 
often used after their expiry date, adds 
to the complexity of the problem.2 This 
has been further compounded by factors 
in secondary care including hospital 
over-crowding leading to cross-infection, 
immunosuppression (due to disease or its 
treatment) and the use of more invasive 
techniques which provide access for easy 
entry of bacteria into the patient’s body.3 
Despite improvements in immunization, 
infection control policies and medical 
practice amongst others, the rate of 
emergence of resistant strains has 
continued to rise, with a nearly 2% 
increase in resistance among Gram- positive 
pathogens in the United States over a 
ten year period. The most common drug 
resistant Gram-positive pathogens are 
staphylococci, enterococci and streptococci 
with meticillin resistant Staphylococcus 
aureus (MRSA), vancomycin resistant 
Staphylococcus aureus (VRSA) and 
vancomycin resistant Enterococcus species 
(VRE) offering the greatest challenge to 
health care and causing potentially life-
threatening infections. Multi-drug-resistant 
Streptococcus pneumoniae has also been 
reported. Reports indicate that more than 
2% of Staphylococcus aureus infections in 
Europe are caused by MRSA, with most of 
these isolates being multi-drug resistant.6 
The European Union has voiced its concern 
about this alarming increase in antibiotic 
resistance and has launched a surveillance 
programme, the European Antimicrobial 
Resistance Surveillance System (EARSS). 
A recent report summarising trends over 
the past seven years (1999 to 2006), has 
indicated that there continues to be a 
loss of antimicrobial effectiveness which 
does not seem to have slowed down, with 
resistance and a reduction in antimicrobial 
effectiveness reported both in community 
and in hospital-based care.7
The purpose of this review is to describe 
some of the newer compounds targeting 
mainly Gram-positive organisms, including 
multi-drug resistant strains. The review will 
also briefly describe some compounds in 
various stages of clinical development.
Daptomycin
Daptomycin is a fermentation product 
produced by Streptomyces roseosporus. It 
was originally discovered by Eli Lilly in the 
1980s and given the name deptomycin, 
which was later changed due to potential 
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confusion with the names of other 
compounds such as streptomycin. Following 
Phase I and Phase II trials, Lilly abandoned 
the development of daptomycin; this was 
then taken up by Cubist Pharmaceuticals 
in 1997 primarily as a response to the 
increasing threat of resistance by Gram-
positive bacteria.
Daptomycin is a cyclic lipopeptide 
antibiotic with a unique structure, giving 
it an equally unique mode of action 
on the bacterial cell wall. Its proposed 
mechanism of action involves the insertion 
of the lipophilic tail into the bacterial cell 
membrane causing formation of a channel 
in the presence of calcium, resulting in 
depolarisation of the membrane. This results 
in potassium efflux causing inhibition 
of protein, DNA and RNA synthesis and 
subsequently cell death.,6 It is bactericidal 
with activity against most Gram-positive 
bacteria; this includes both antibiotic-
susceptible and resistant strains. In the 
US, it has been licensed for treatment 
in adults of complicated skin and skin-
structure infections (cSSTI) associated 
with Staphylococcus aureus, streptococci 
and vancomycin-susceptible Enterococcus 
faecalis.6 More recently, it has also been 
licensed for treatment of Staphylococcus 
aureus bloodstream infections including 
right-sided endocarditis.8 In the UK it is 
licensed only for use in cSSTI in adults.9 
It has no activity against Gram-negative 
bacteria since it is unable to penetrate 
the bacterial cell wall. Consequently, it 
should not be administered as monotherapy 
where mixed infections are suspected. 
When compared to vancomycin, linezolid 
and quinipristin-dalfopristin, daptomycin 
had a greater bactericidal activity 
against Staphylococcus and Enterococcus 
species. It has shown in vitro synergy 
with aminoglycosides and rifampicin.6 
Despite limited availability on the market, 
reduced susceptibility to daptomycin by 
Staphylococcus aureus has been observed 
and was associated with prolonged use and 
the presence of foreign devices that could 
not be removed.8
The dose giving maximum efficacy 
and safety is mg/kg daily as a once daily 
intravenous infusion, possibly due to the 
prolonged post-antibiotic effect of more 
than 6 hours. In healthy volunteers it has 
a half life of 8 hours. It is excreted renally 
and consequently the dosage interval 
should be increased to every 8 hours in 
renal impairment where the creatinine 
clearance is <30ml/min or in patients on 
haemodialysis or continuous ambulatory 
peritoneal dialysis, where the half life 
increases to 28 hours.9 Since it is not 
hepatically metabolised, it does not cause 
any interactions related to the cytochrome 
P-0 enzyme system.,6 It does not 
cross the blood brain barrier or enter the 
cerebrospinal fluid in normal individuals. 
Bone penetration is poor and daptomycin 
should therefore not be used in central 
nervous system or bone infections.10 It 
has also not been effective in pneumonia, 
primarily due to daptomycin inactivation by 
lung surfactant.8
Myopathy has been reported with higher 
plasma concentrations and is associated 
with the release of creatine phosphokinase 
(CPK) by skeletal muscle. This is not 
progressive and is reversible on withdrawal 
of the drug. To ensure safe administration, 
it is recommended to measure plasma CPK 
at baseline and at least once weekly during 
therapy in all patients; this should be done 
more often in patients with increased risk 
of developing myopathy such as patients 
with renal impairment. Caution should 
also be exercised when daptomycin is co-
administered with medications that may 
increase the risk of myopathy (including 
HMG-CoA reductase inhibitors, fibrates and 
ciclosporin). Peripheral neuropathy has also 
been reported, and daptomycin should be 
stopped in any patients reporting symptoms 
of this condition.9 Safety in pregnancy, 
lactation and children has not yet been 
established.
Compared to other newer agents, one 
of the main advantages of daptomycin is 
that it is bactericidal. Besides, it is the 
first drug with bactericidal activity against 
Enterococcus and may offer an alternative 
to vancomycin-resistant Enterococcus 
endocarditis, though more evidence on this 
is needed.10  The myopathy it produces as an 
adverse effect is dose-dependent and is not 
expected at the recommended dose, unlike 
quinipristin-dalfopristin where myopathy 
may occur at therapeutic doses.10 It offers 
advantages over vancomycin in that it 
is administered once daily and does not 
require any therapeutic drug monitoring.
Linezolid
Linezolid is the first of a new class of 
antibacterial agents called oxazolidinones.11 
Its antibacterial activity is due to an 
inhibitory effect on protein synthesis. It 
disrupts the interaction of fMet-tRNA onto 
the bacterial ribosome which is important 
for the initial phase of protein translation.12 
Hence, it has no effect on bacterial 
replication or transcription of DNA to RNA. 
Linezolid is bacteristatic. It has 
good activity against Gram-positive 
bacteria, including MRSA, glycopeptide-
intermediate Staphylococcus aureus (GISA), 
VRE and penicillin-resistant Streptococcus 
pneumoniae. Moreover, it is also active 
against anaerobes, such as Clostridium 
perfringens and Peptostreptococcus species.11
The drug is available in both oral 
and intravenous forms.13 The oral dose is 
600mg bd. Bioavailability following oral 
administration is 100% and absorption is 
not affected by food.11 Elimination half 
life of the drug is . to . hours after a 
steady state has been reached.11
Although bacteristatic, linezolid has an 
important role in the treatment of serious 
Gram-positive infections. Its use is mainly 
in cases of multi-drug resistant infections 
such as MRSA, GISA and VRE. Hence, it 
is more likely to be used in the hospital 
setting. Currently, the approved indications 
for use of linezolid include hospital-acquired 
pneumonia (especially ventilator-associated 
pneumonia) and cSSTI.13
A number of trials have been carried 
out in order to assess the efficacy of 
linezolid compared to other well established 
treatment regimens, including a randomized 
control trial comparing linezolid with 
vancomycin in the treatment of cSSTI.1 
The results showed that the two drugs 
were equivalent in the intention-to-treat 
analysis. However, linezolid was noted 
to be superior where MRSA was isolated 
and in those patients with abscesses and 
surgical site infections secondary to MRSA. 
The authors of this paper suggest that the 
better outcome with linezolid could be due 
to better penetration of the drug into skin 
and subcutaneous tissue.
In an anaylsis of two double-blind 
randomised trials of patients with MRSA-
documented hospital-acquired pneumonia, 
linezolid was noted to have a higher 
rate of cure and a lower mortality than 
vancomycin.1 There was no difference 
between the two for meticillin-sensitive 
Staphylococcus aureus (MSSA) infections. 
As with cSSTI, it is thought that linezolid 
penetrates lung tissue better than 
vancomycin. As a result of this study and 
two others based on tissue penetration of 
linezolid, the American Thoracic Society’s 
guidelines on the treatment of hospital-
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acquired pneumonia suggest that patients 
with documented MRSA pneumonia could be 
treated with either vancomycin or linezolid, 
but the latter should be preferred if patients 
have renal impairment or are at risk of 
nephrotoxicity.16
There are also case reports of linezolid 
being used in other disease states, 
such as infective endocarditis17, central 
nervous system infections18 and bone/joint 
infections19, but its use has been hampered 
by a lack of safety data on long term use. 
Adverse events associated with linezolid 
use include anaemia, neutropaenia, 
thrombocytopaenia, deranged liver 
function, headaches and gastrointestinal 
disturbances.20 It is recommended that 
patients who are on linezolid should have 
their full blood count checked every week 
whilst on treatment, especially if the 
duration of the antibiotic continues beyond 
the recommended maximum of 28 days.13
Linezolid is an inhibitor of monoamine 
oxidase inhibitors (MAOI). Hence, it should 
be avoided in patients on MAOIs unless it is 
given under close supervision.13 There have 
also been reports of the serotonin syndrome 
when the antibiotic was administered with 
serotonin reuptake inhibitors (SSRI); this 
can occur early during treatment in young 
patients but later in older patients.21
Although linezolid is a novel antibiotic 
with a different site of action than any 
other antibiotic, resistance has been seen 
in some cases. Most of the cases have 
been noted in patients who have either 
indwelling prosthetic devices or have 
been receiving prolonged courses of the 
antibiotic.22
Tigecycline
Tigecycline belongs to a class of drugs, 
closely related to tetracycline, called 
glycylcyclines. It inhibits protein synthesis 
by binding to the 30S ribosomal subunit 
and preventing the addition of transfer 
RNA molecules required for the elongation 
phase.23 
Tigecycline is a bacteristatic drug.2 In 
this respect, it is similar to linezolid. Its 
antibacterial spectrum is however much 
more extensive, with excellent activity 
not only against Gram-positive organisms 
but also against Gram-negatives. It is 
very potent against MRSA, VRE, meticillin-
resistant Staphylococcus epidermidis 
and streptococci (including penicillin-
resistant strains). Moreover, it is active 
against many Gram-negatives including 
Enterobacteriaceae and  multidrug 
resistant Acinetobacter baumannii and 
Stenotrophomonas maltophilia. On the other 
hand, it has reduced activity against Proteus 
and Pseudomonas aeruginosa.2  
Tigecycline is only available as an 
intravenous preparation because oral 
bioavailability is poor.23 The currently 
recommended dose is a 100mg loading dose 
followed by 0mg twice daily. The half life 
in humans ranges between 37 and 67 hours. 
It is widely distributed in the body with 
concentrations in skin and lungs reaching 
three times that of plasma in experimental 
rats.26 Tigecycline circulates as unchanged 
drug in serum. It is eliminated through 
the gut and hence, does not need any dose 
adjustment in patients with renal failure.27
The current indications for tigecycline 
are cSSTI and complicated intra-abdominal 
infections.2 In the case of cSSTI, results 
from two phase 3 randomised, double-
blinded studies were pooled and analysed.28 
Patients were treated with either tigecycline 
monotherapy or vancomycin plus aztreonam 
for up to 1 days. The results showed 
that tigecycline was as effective as the 
comparator arm. On the other hand, in 
the case of complicated intra-abdominal 
infections both Gram-positive and Gram-
negatives are important in the pathogenesis 
of this disease. In a pooled analysis from 
two Phase 3 studies between tigecycline 
monotherapy versus imipenem-cilastatin 
in 162 adults with complicated intra-
abdominal infections, it was shown 
that tigecycline was non-inferior to the 
comparator arm.29  
Tigecycline is very well tolerated. The 
most frequent adverse events reported to 
date include nausea and vomiting, resulting 
in discontinuation of treatment in % of 
cases.30 Other relevant events are transient 
elevations of alanine aminotransferase, 
aspartate aminotransferase and alkaline 
phosphatase, which are all markers of 
hepatic function. 
There are very few drug interactions of 
clinical significance, when administering 
tigecycline. Since it is not metabolised by 
the liver there is no effect on drugs acting 
on the cytochrome P0 enzyme system.23 
Although tigecycline may prolong both 
prothrombin time and activated partial 
thromboplastin time, there is no evidence to 
suggest that this may result in a significant 
change in the INR. However, it is advisable 
that patients on warfarin should be more 
closely monitored if they are administered 
tigecycline concurrently.2
Currently, resistance to tigecycline 
is not a major problem. It is known that 
tigecycline binds more avidly to ribosomes 
than tetracycline and hence can overcome 
the resistance methods employed against 
the latter. However, resistance can emerge 
in microorganisms that are able to express 
the multi-drug efflux pump normally 
associated with Gram-negatives.31 
Other	antibiotics	under	development
With the emergence of ever more drug 
resistant microorganisms, the need for 
developing more active drugs is a real 
emergency. The antibiotics mentioned above 
have all been approved for specific clinical 
indications. There are other investigational 
drugs which are at different stages of 
development. Their main target is multi-
drug resistant bacteria. 
•	 Dalbavancin is a semisynthetic 
glycopeptide with a similar mode of 
action to vancomycin. It has potent 
activity against Gram-positive organisms 
including MRSA.32 This drug is remarkable 
for its long half life of 8. days and 
can therefore be used once weekly. In 
a number of trials involving this drug, 
it was administered on day 1 and day 8 
only for cSSTI.33,3 This drug could be very 
useful in the outpatient treatment of 
cSSTIs. Its long half-life may be a major 
drawback since if there is a drug related 
reaction, its effects will last for a number 
of days and cannot be reversed by simply 
stopping the drug. 
• Other semisynthetic glycopeptides 
used against Gram-positive organisms 
including MRSA are under investigation. 
Telavancin is rapidly bactericidal and 
exists as an intravenous preparation to 
be given once daily. Its current indication 
is in cSSTI.3 Oritavancin	is still in a 
Phase 3 study. Its indications are likely 
to include cSSTI, catheter-associated 
infections and endocarditis. Because of 
a long half life, it is likely that it will 
be dosed on a daily or alternate day 
schedule.32
•  Ceftobiprole	is a novel bactericidal 
cephalosporin being developed for the 
treatment of Gram-positive organisms, 
including MRSA, whilst maintaining 
the Gram-negative cover of the third 
generation cephalosporins. At the time 
of writing, the drug  is in a Phase 3 
trial and the indications are thought to 
include cSSTI.36 
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•	 Iclaprim	is a new dihydrofolate reductase 
inhibitor belonging to the same class of 
antibiotics as trimethoprim. Its Gram-
positive cover is very promising with 
potent activity against MRSA, VISA and 
VRSA. It is currently in development 
as an intravenous agent; however, oral 
bioavailability is good and there are 
Phase I trials with an oral preparation 
which would allow intravenous-to-oral 
switch.37   
Conclusion
As more resistant organisms are being 
seen in clinical practice, there is an urgent 
need for more potent antibiotics. There 
are only a few drugs which belong to a 
completely novel class; the rest are only a 
• New antibiotics are being produced to target multi-drug resistant bacteria.
• Most of these drugs are aimed at the in-patient management of serious infections.
• Pharmacists should be aware of the interactions and adverse effect profiles of these 
new drugs as their use is likely to increase in the future.
• Prudent and optimal use of antibiotics may help to limit the development of 
resistance; pharmacists should play a vital role to ensure optimal prescribing of 
antibiotics, both in hospital and community environments.
Practice	Points
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development of old and existing classes. 
If we do not take good care of the existent 
antibiotics by responsible prescribing, we 
will be at risk of losing even these more 
efficacious antibiotics.
